ScholarLens Back to search
2017•Kidney International ReportsOpen access

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy

Karine Dahan, Valentine Gillion, Catherine Johanet, Hanna Dêbiec, Pierre Ronco

Open full text 20 citations

Abstract

Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Some cases are associated with malignancy, infections, autoimmune systemic diseases, or drugs, but most are of an autoimmune nature, being referred to as primary (PMN).1 The natural course is variable and unpredictable: approximately one-third of patients with PMN undergo spontaneous remission,2 whereas most patients with persisting nephrotic syndrome will progress to end-stage renal disease within 10 years.

About this research paper

What this paper is about

Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Some cases are associated with malignancy, infections, autoimmune systemic diseases, or drugs, but most are of an autoimmune nature, being referred to as primary (PMN).1 The natural course is variable and unpredictable: approximately one-third of patients with PMN undergo spontaneous remission,2 whereas most patients with persisting nephrotic syndrome will progress to end-stage renal disease within 10 years.

Why it matters

OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Some cases are associated with malignancy, infections, autoimmune systemic diseases, or drugs, but most are of an autoimmune nature, being referred to as primary (PMN).1 The natural course is variable and unpredictable: approximately one-third of patients with PMN undergo spontaneous remission,2 whereas most patients with persisting nephrotic syndrome will progress to end-stage renal disease within 10 years.

Key concepts: Medicine, Nephrotic syndrome, Membranous nephropathy, Malignancy, Antibody, Spontaneous remission, Glomerulonephritis, Disease

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The Role of PLA2R Antibody in Treatment of Membranous Nephropathy — Research Paper | ScholarLens